Literature DB >> 16585163

3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis.

Juliana J Oh1, Ali Razfar, Idolina Delgado, Rebecca A Reed, Anna Malkina, Baher Boctor, Dennis J Slamon.   

Abstract

Deletion at chromosome 3p21.3 is the earliest and the most frequently observed genetic alteration in lung cancer, suggesting that the region contains tumor suppressor gene(s) (TSG). Identification of those genes may lead to the development both of biomarkers to identify high-risk individuals and novel therapeutics. Previously, we cloned the H37/Luca15/RBM5 gene from 3p21.3 and showed its TSG characteristics. To investigate the physiologic function of H37 in the lung and its mechanism of tumor suppression, we have stably transfected H37 into A549 non-small cell lung cancer cells. A549/H37 cells show significant growth inhibition compared with the vector controls by in vitro and in vivo cell proliferation assays. Using this lung cancer cell model, we have found that the molecular mechanism of H37 tumor suppression involves both cell cycle (G(1)) arrest and apoptosis. To further define H37's function in cell cycle/apoptotic pathways, we investigated differential expression profiles of various cell cycle and apoptosis regulatory proteins using Western blot analysis. Both cyclin A and phophorylated RB levels were decreased in H37-transfected cells, whereas expression of Bax protein was increased. Mitochondrial regulation of apoptosis further downstream of Bax was investigated, showing change in the mitochondrial membrane potential, cytochrome c release into the cytosol, and enhanced caspase-9 and caspase-3 activities. We also report that H37 may mediate apoptosis in a p53-independent manner, and Bax knockdown by small interfering RNA suggests Bax plays a functional role downstream of H37. Lastly, we proposed a tumor suppression model of H37 as a post-transcriptional regulator for cell cycle/apoptotic-related proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585163     DOI: 10.1158/0008-5472.CAN-05-1667

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

Review 1.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

2.  The emerging role of splicing factors in cancer.

Authors:  Ana Rita Grosso; Sandra Martins; Maria Carmo-Fonseca
Journal:  EMBO Rep       Date:  2008-10-10       Impact factor: 8.807

3.  Differential downregulation of Rbm5 and Rbm10 during skeletal and cardiac differentiation.

Authors:  Julie J Loiselle; Leslie C Sutherland
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-11-01       Impact factor: 2.416

4.  Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A.

Authors:  Anna Corrionero; Belén Miñana; Juan Valcárcel
Journal:  Genes Dev       Date:  2011-03-01       Impact factor: 11.361

5.  Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins.

Authors:  Akihide Yoshimi; Omar Abdel-Wahab
Journal:  Clin Cancer Res       Date:  2016-11-10       Impact factor: 12.531

Review 6.  KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.

Authors:  Javier de Castro Carpeño; Cristóbal Belda-Iniesta
Journal:  Transl Lung Cancer Res       Date:  2013-04

7.  Co-existence of isodicentric Ph chromosomes and the three-way Ph chromosome variant t(3;9;22)(p21;q34;q11) in a rare case of chronic myeloid leukemia.

Authors:  Qian Li; Xiao-Ji Lin; Hui Chen; Jian Gong; Zhen Li; Xiang-Nan Chen
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

8.  Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus.

Authors:  Juliana J Oh; Baher N Boctor; Cynthia A Jimenez; Roberto Lopez; Ashley K Koegel; Eileen O Taschereau; Diana T Phan; Steven E Jacobsen; Dennis J Slamon
Journal:  Hum Genet       Date:  2007-11-22       Impact factor: 4.132

9.  Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5.

Authors:  Kazuo Fushimi; Payal Ray; Amar Kar; Lei Wang; Leslie C Sutherland; Jane Y Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-07       Impact factor: 11.205

Review 10.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.